Observing real-world care of patients with transthyretin amyloidosis
Follows adults with ATTR amyloidosis, a rare protein-build-up disease, and their treatments over time.
Plain-language title generated from the registry record
Registry title: Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Key facts
- Where
- Beijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Shaanxi, Shanghai, Shijiazhuang, Suzhou, Taiyuan, Wuhan, and Xiamen, ChinaSee the 20 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a confirmed diagnosis of transthyretin (ATTR) amyloidosis who have symptoms. It follows them over time and records their real-world care and outcomes.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Confirmed ATTR amyloidosis with symptoms. People with no symptoms cannot join.
Main reasons for not taking part
- Taking part in another interventional trial for ATTR amyloidosis
- Signs of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)
- No symptoms of ATTR amyloidosis, including people who only carry an ATTR mutation
- Being involved in planning or running this study
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 130 years old?
Source: NCT06465810, who can take part
Where in China
- BeijingBeijing, ChinaTaking people
- ChangshaChangsha, ChinaTaking people
- ChengduChengdu, ChinaTaking people
- ChongqingChongqing, ChinaTaking people
- DalianDalian, ChinaNot yet recruiting
- FuzhouFuzhou, ChinaNot yet recruiting
- GuangzhouGuangzhou, ChinaTaking people
- GuiyangGuiyang, ChinaNot yet recruiting
- HangzhouHangzhou, ChinaNot yet recruiting
- HefeiHefei, ChinaNot yet recruiting
- JinanJinan, ChinaTaking people
- NanchangNanchang, ChinaTaking people
- NanjingNanjing, ChinaTaking people
- ShaanxiShaanxi, ChinaTaking people
- ShanghaiShanghai, ChinaTaking people
- ShijiazhuangShijiazhuang, ChinaNot yet recruiting
- SuzhouSuzhou, ChinaNot yet recruiting
- TaiyuanTaiyuan, ChinaNot yet recruiting
- WuhanWuhan, ChinaTaking people
- XiamenXiamen, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06465810
- Record updated
- 23 September 2026
- Original description
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.Read full original descriptionShow less
A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
Inclusion: Patient willing and able to provide written informed consent to participate in the study; Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis; Aged ≥18 years at the time of signing the informed consent; Patient willing and able to participate in collection of electronic patient reported outcomes (PROs).
Exclusion: Concurrent participation in any interventional trial for ATTR amyloidosis; Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA); Involvement in the planning and/or conduct of the current study; Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers.